Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 EPS of $0.00, $0.19 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $47.6 million versus the consensus estimate of $4.9 million.

For earnings history and earnings-related data on Adaptimmune Therapeutics (ADAP) click here.